Stock Price Movement and Volatility
On 24 Nov 2025, Mangalam Drugs and Organics traded with notable volatility, registering an intraday price range between Rs 44.82 and Rs 49.79. Despite opening with a gap up of 7.65%, the stock ultimately closed close to its 52-week low, just 0.91% above Rs 44.61. This price action highlights the stock’s struggle to maintain upward momentum amid selling pressure. The intraday volatility measured at 8.07% underscores the heightened uncertainty surrounding the stock’s near-term direction.
The stock has experienced a consecutive decline over the past five trading sessions, resulting in a cumulative return of -27.15% during this period. This sustained downward trend contrasts with the broader market, where the Sensex has recorded a positive trajectory, gaining 0.22% on the same day and showing a 2.65% rise over the last three weeks.
Technical Indicators and Moving Averages
Mangalam Drugs and Organics is currently trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This positioning suggests a prevailing bearish sentiment in the stock’s price action. In contrast, the Sensex is trading above its 50-day moving average, with the 50 DMA positioned above the 200 DMA, indicating a more bullish market environment for large-cap indices.
This week's revealed pick, a Large Cap from Public Banks with TARGET PRICE, is already showing movement! Get the complete analysis before it's too late.
- - Target price included
- - Early movement detected
- - Complete analysis ready
Financial Performance and Profitability Metrics
The company’s financial results have reflected ongoing pressures, with net sales for the latest quarter reported at Rs 49.54 crore, marking the lowest quarterly sales figure recorded recently. The net profit after tax (PAT) for the quarter stood at a loss of Rs 7.35 crore, representing a decline of 201.2% compared to the previous four-quarter average. Interest expenses have reached Rs 5.03 crore, the highest level in recent quarters, further impacting profitability.
Return on Equity (ROE) averaged at 7.99%, indicating modest profitability relative to shareholders’ funds. The company’s ability to service debt remains constrained, with an average EBIT to interest ratio of 1.36, signalling limited coverage of interest obligations by operating earnings.
Long-Term Performance and Market Comparison
Over the past year, Mangalam Drugs and Organics has recorded a total return of -57.63%, significantly underperforming the Sensex, which has shown a positive return of 7.97% over the same period. The stock’s 52-week high was Rs 129.90, illustrating the extent of the decline from its peak levels. This underperformance extends over multiple years, with the stock trailing the BSE500 index in each of the last three annual periods.
Shareholding and Risk Factors
Promoter shareholding includes a substantial proportion of pledged shares, currently at 34.58%. This represents an increase of 21.35% over the last quarter, which may exert additional downward pressure on the stock price in volatile market conditions. The elevated level of pledged shares is a factor that market participants often monitor closely due to its potential implications for share liquidity and price stability.
Considering Mangalam Drugs and Organics ? Wait! SwitchER has found potentially better options in Pharmaceuticals & Biotechnology and beyond. Compare this micro-cap with top-rated alternatives now!
- - Better options discovered
- - Pharmaceuticals & Biotechnology + beyond scope
- - Top-rated alternatives ready
Sector and Market Context
Mangalam Drugs and Organics operates within the Pharmaceuticals & Biotechnology sector, which has experienced mixed performance in recent months. While the broader market indices such as the Sensex have shown resilience and positive momentum, the company’s stock has diverged notably from this trend. The sector’s overall performance is influenced by various factors including regulatory developments, research and development outcomes, and competitive dynamics.
Summary of Key Price and Performance Metrics
As of the latest trading session, the stock’s closing price is within 1% of its 52-week low of Rs 44.61. The stock’s day change was -3.59%, underperforming its sector by 2.53%. The intraday high of Rs 49.79 contrasts with the low of Rs 44.82, reflecting significant price swings during the session. The stock’s market capitalisation grade is noted as 4, indicating its relative size and liquidity profile within the market.
Despite the broader market’s positive trajectory, Mangalam Drugs and Organics continues to face headwinds that have contributed to its current valuation levels. The stock’s performance over the past year and recent quarters highlights the challenges faced by the company in maintaining sales growth and profitability.
Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →
